Bruker Corporation develops high-performance scientific instruments and analytical and diagnostic solutions for life science, applied, biopharma, microscopy, nanoanalysis, industrial, cleantech and semiconductor metrology markets.
Recurring news for BRKR includes earnings updates for Bruker Scientific Instruments and Bruker Energy & Supercon Technologies, product launches across NMR, microbiology, infection diagnostics, spatial biology and AFM-IR spectroscopy, and governance changes. Company announcements also cover platforms such as MALDI Biotyper, IR Biotyper, MyGenius PRO, GeoMx, CellScape, CosMx and Dimension IconIR.
Bruker Corporation (Nasdaq: BRKR) has introduced the Vutara VXL Super-Resolution Fluorescence Microscope, aimed at enhancing affordable, super-resolution imaging in biological research. This innovative system employs Bruker’s leading single-molecule localization technology, facilitating advanced studies of DNA, RNA, and proteins, as well as complex biological structures. Key features include high spatial resolution, multiplexing capabilities, and integrated analytical software, making it suitable for various research applications. The company aims to broaden access to 3D microscopy for the scientific community, potentially advancing cellular biology research.
Bruker Corporation (Nasdaq: BRKR) will release its third quarter 2020 financial results on November 2, 2020, after market close. A conference call will follow at 4:30 p.m. Eastern Time to discuss these results and current business trends. Investors can participate via webcast or telephone. Pre-registration is available to streamline entry. A replay of the call will be accessible until December 2, 2020, using the provided conference number.
Bruker Corporation (Nasdaq: BRKR) has launched the Fourier™ 80, an 80 MHz benchtop FT-NMR spectrometer, in Europe. The device features gradient spectroscopy and an optional CTC PAL® sample changer, enhancing throughput and efficiency. With a novel 80 MHz permanent magnet, it eliminates the need for cryogens and cooling. The new model offers 20% improved resolution, making it suitable for chemistry labs and educational purposes. Dr. Falko Busse emphasizes its role in democratizing FT-NMR applications, enabling greater accessibility for both research and teaching.
Summary not available.
Bruker Corporation (Nasdaq: BRKR) has acquired the Integrated Proteomics Pipeline (IP2) developed by Integrated Proteomics Applications Inc. This acquisition enhances Bruker's bioinformatics capabilities, supporting its innovative CCS-enabled 4D-Proteomics™. The IP2 allows fast, scalable data processing, increasing confidence in protein identification and quantification. Bruker will establish a San Diego-based bioinformatics team led by Robin Park, enhancing collaborations with the Yates Lab. Financial terms of the acquisition remain undisclosed.